{"id":72342,"date":"2026-08-12T11:42:57","date_gmt":"2026-08-12T03:42:57","guid":{"rendered":"https:\/\/flcube.com\/?p=72342"},"modified":"2026-08-12T11:42:58","modified_gmt":"2026-08-12T03:42:58","slug":"impact-therapeutics-signs-exclusive-deal-with-pharmanovia-for-senaparib-parp-inhibitor-across-66-countries-worth-up-to-eur-423-5-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72342","title":{"rendered":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>IMPACT Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/7630:HKG\">HKG: 7630<\/a>) announced an <strong>exclusive partnership<\/strong> with <strong>Pharmanovia<\/strong> for <strong>senaparib<\/strong> (brand name: <strong>Paishuning<\/strong>), a <strong>novel, highly active PARP1\/2 inhibitor<\/strong> independently developed by IMPACT. The Marketing Authorization Application (<strong>MAA<\/strong>) for <strong>first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe<\/strong> was <strong>accepted by the European Medicines Agency (EMA) in August 2025<\/strong>, with <strong>approval expected in the second half of 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>IMPACT Therapeutics, Inc. (HKG: 7630) \/ Pharmanovia<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive partnership (manufacture, development, commercialization)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Senaparib (brand: Paishuning), novel PARP1\/2 inhibitor<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Monotherapy for maintenance treatment of advanced epithelial high\u2011grade ovarian, fallopian tube, and primary peritoneal cancer<\/td><\/tr><tr><td><strong>Territories<\/strong><\/td><td>66 countries, including all 27 EU members, UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and MENA region<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to EUR 423.5 million (upfront + regulatory and commercialization milestones)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, up to mid\u2011twenties percentage on net product sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-regulatory-status\" class=\"wp-block-heading\">Product Profile &amp; Regulatory Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Senaparib<\/strong>, a novel, highly active <strong>PARP1\/2 inhibitor<\/strong> independently developed by IMPACT Therapeutics.<\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>First\u2011line maintenance treatment<\/strong> of adult patients with <strong>advanced ovarian cancer<\/strong> (also covering fallopian tube and primary peritoneal cancer in the licensed scope).<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> MAA <strong>accepted by the EMA in August 2025<\/strong>; <strong>approval expected in H2 2026<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> A next\u2011generation PARP inhibitor entering an established maintenance\u2011therapy market currently served by olaparib, niraparib, and rucaparib.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-terms\" class=\"wp-block-heading\">Commercial Terms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Rights:<\/strong> IMPACT granted Pharmanovia <strong>exclusive rights for the manufacture, development, and commercialization<\/strong> of senaparib as a <strong>monotherapy<\/strong> for the specified indication.<\/li>\n\n\n\n<li><strong>Territory Coverage:<\/strong> <strong>66 countries<\/strong> \u2014 all <strong>27 EU member states<\/strong>, plus the <strong>UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand<\/strong>, and countries across the <strong>Middle East and North Africa (MENA)<\/strong> region.<\/li>\n\n\n\n<li><strong>Payment Structure:<\/strong> IMPACT is eligible to receive <strong>total payments of up to EUR 423.5 million<\/strong>, comprising an <strong>upfront payment<\/strong>, <strong>near\u2011term regulatory milestone payments<\/strong>, and <strong>commercialization milestone payments<\/strong> upon achieving corresponding sales thresholds.<\/li>\n\n\n\n<li><strong>Royalties:<\/strong> <strong>Tiered royalties up to the mid\u2011twenties percentage<\/strong> based on net product sales.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ovarian Cancer Maintenance Market:<\/strong> First\u2011line maintenance PARP therapy has become the standard of care in advanced ovarian cancer, creating a large and durable global market.<\/li>\n\n\n\n<li><strong>Broad Geographic Reach:<\/strong> Coverage of 66 markets through a single partner positions senaparib for rapid international rollout following the anticipated EMA decision in H2 2026.<\/li>\n\n\n\n<li><strong>China Biotech Out\u2011Licensing Signal:<\/strong> The deal \u2014 among the larger European out\u2011licensing agreements for a Chinese\u2011developed PARP inhibitor \u2014 underscores continued global appetite for Chinese oncology assets.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory timing, milestone achievement, and commercial expectations for senaparib. Actual results may differ due to risks including the EMA decision, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,4765,961,2205],"class_list":["post-72342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-hkg-7630","tag-impact-therapeutics","tag-pharmanovia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72342\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million\" \/>\n<meta property=\"og:description\" content=\"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72342\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T03:42:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T03:42:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million\",\"datePublished\":\"2026-08-12T03:42:57+00:00\",\"dateModified\":\"2026-08-12T03:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1202.webp\",\"keywords\":[\"Cancer\",\"HKG: 7630\",\"Impact Therapeutics\",\"Pharmanovia\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72342#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72342\",\"name\":\"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1202.webp\",\"datePublished\":\"2026-08-12T03:42:57+00:00\",\"dateModified\":\"2026-08-12T03:42:58+00:00\",\"description\":\"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\\\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72342\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72342#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million - Insight, China&#039;s Pharmaceutical Industry","description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72342","og_locale":"en_US","og_type":"article","og_title":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million","og_description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.","og_url":"https:\/\/flcube.com\/?p=72342","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-12T03:42:57+00:00","article_modified_time":"2026-08-12T03:42:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72342#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72342"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million","datePublished":"2026-08-12T03:42:57+00:00","dateModified":"2026-08-12T03:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72342"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72342#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","keywords":["Cancer","HKG: 7630","Impact Therapeutics","Pharmanovia"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72342#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72342","url":"https:\/\/flcube.com\/?p=72342","name":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72342#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72342#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","datePublished":"2026-08-12T03:42:57+00:00","dateModified":"2026-08-12T03:42:58+00:00","description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1\/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first\u2011line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72342#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72342"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72342#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","width":1080,"height":608,"caption":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72342#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1202.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72342"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72342\/revisions"}],"predecessor-version":[{"id":72344,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72342\/revisions\/72344"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72343"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}